4/7
04:05 pm
acrv
Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer
Low
Report
Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer
3/28
08:13 pm
acrv
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
High
Report
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
3/27
05:44 pm
acrv
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results
High
Report
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results
3/26
10:27 am
acrv
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
High
Report
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
3/26
08:19 am
acrv
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its price target lowered by analysts at HC Wainwright from $22.00 to $19.00. They now have a "buy" rating on the stock.
High
Report
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its price target lowered by analysts at HC Wainwright from $22.00 to $19.00. They now have a "buy" rating on the stock.
3/19
08:00 am
acrv
Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates
Medium
Report
Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates
2/5
09:07 am
acrv
Acrivon Therapeutics gets FDA breakthrough device designation for its oncosignature assay for endometrial cancer [Seeking Alpha]
High
Report
Acrivon Therapeutics gets FDA breakthrough device designation for its oncosignature assay for endometrial cancer [Seeking Alpha]
2/5
08:00 am
acrv
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer
High
Report
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer
1/31
10:27 am
acrv
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Low
Report
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
1/31
08:32 am
acrv
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) is now covered by analysts at KeyCorp. They set an "overweight" rating on the stock.
Medium
Report
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) is now covered by analysts at KeyCorp. They set an "overweight" rating on the stock.